4//SEC Filing
Ocata Therapeutics, Inc. 4
Accession 0001104659-16-095976
CIK 0001140098operating
Filed
Feb 10, 7:00 PM ET
Accepted
Feb 11, 4:36 PM ET
Size
21.6 KB
Accession
0001104659-16-095976
Insider Transaction Report
Form 4
Lanza Robert
Chief Scientific Officer
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2016-02-10−17,834→ 0 totalExercise: $19.50Exp: 2021-01-10→ Common Stock (17,834 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2016-02-10−150,000→ 0 totalExercise: $15.70Exp: 2021-08-08→ Common Stock (150,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2016-02-10−12,858→ 0 totalExercise: $6.20Exp: 2023-11-08→ Common Stock (12,858 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2016-02-10−35,334→ 0 totalExercise: $8.49Exp: 2024-09-12→ Common Stock (35,334 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2016-02-10−76,666→ 0 totalExercise: $8.49Exp: 2024-09-12→ Common Stock (76,666 underlying) - Disposition from Tender
Common Stock
2016-02-10$8.50/sh−231,509$1,967,827→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2016-02-10−40,000→ 0 totalExercise: $21.00Exp: 2018-02-07→ Common Stock (40,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2016-02-10−53,500→ 0 totalExercise: $9.80Exp: 2019-11-13→ Common Stock (53,500 underlying)
Footnotes (3)
- [F1]On November 10, 2015, Ocata Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Laurel Acquisition Inc., an indirect wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company in a merger (the "Merger") that became effective on February 10, 2016.
- [F2]Pursuant to the Merger Agreement, all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive a cash payment equal to $8.50 per share (the "Offer Price"), and all shares of Company restricted stock units outstanding immediately prior to the Effective Time, whether vested or unvested, were canceled and converted automatically into the right to receive a cash payment equal to the Offer Price. Includes 32,667 shares of Company common stock issued upon the settlement of restricted stock units.
- [F3]Pursuant to the Merger Agreement, each Company stock option outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was canceled and converted automatically into the right to receive a cash payment with respect thereto equal to the product of (i) the number of shares of Company common stock subject to such Company stock option immediately prior to the Effective Time and (ii) the excess, if any, of $8.50 over the exercise price per share subject to such Company stock option immediately prior to the Effective Time. Company stock options in respect of which the exercise price per share equaled or exceeded $8.50 were cancelled, in accordance with the terms of the applicable equity incentive plan and award agreement, for no consideration as of the Effective Time.
Documents
Issuer
Ocata Therapeutics, Inc.
CIK 0001140098
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001140098
Filing Metadata
- Form type
- 4
- Filed
- Feb 10, 7:00 PM ET
- Accepted
- Feb 11, 4:36 PM ET
- Size
- 21.6 KB